薄荷醇修饰的瑞脂酶具有针对大脑的功能,用于治疗老年阿尔茨海默病的治疗
Wan-Ying Liu1, Yang Yu1, Juan Zang1
1School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China.
ACS chemical neuroscience
|May 23, 2024
概括
薄荷醇修饰的氨酸脂质体有效地穿越血脑屏障,减少老年小鼠的氧化应激和神经炎症. 这种新型的输送系统可以提高脑中的素水平,保护神经元并改善认知功能.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 老化的大脑经历氧化应激和神经炎症,与神经退行性疾病如阿尔茨海默病 (AD) 有关.
- 血脑屏障 (BBB) 阻碍了治疗药物向大脑输送,用于AD治疗.
- 薄荷醇 (男性) 已经显示出增加BBB透性的潜力.
研究的目的:
- 开发一种新的脂质体药物递送系统,以增强奎尔素 (Qu) 进入大脑.
- 在老年小鼠模型中研究薄荷醇修饰的素脂质体 (Men-Qu-Lips) 的疗效.
主要方法:
- 薄荷醇被表面修改到封装氨酸的脂质体上,以创建Men-Qu-Lips.
- 评估了脂质体穿越BBB的能力,稳定性和封装效率.
- 在老年小鼠中评估了对氧化应激,神经炎症,神经元保护和认知功能的治疗效果.
主要成果:
- 男人-Qu-唇表现出高封装效率和稳定性.
- 脂质体成功透了血脑屏障.
- 治疗Men-Qu-Lips显著降低了老老鼠大脑中的氧化应激和神经炎症.
- 在老年小鼠中,Men-Qu-Lips提供神经保护,改善学习和记忆能力.
结论:
- 在治疗与年龄相关的神经退行症时,用薄荷醇修饰的氨酸脂质体是克服BBB限制的有希望的策略.
- 这种方法提高了向大脑输送氨酸的速度,为阿尔茨海默病等疾病提供治疗效益.
相关概念视频
Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465


